2.14
Schlusskurs vom Vortag:
$1.92
Offen:
$1.95
24-Stunden-Volumen:
841.60K
Relative Volume:
1.10
Marktkapitalisierung:
$154.77M
Einnahmen:
$6.96M
Nettoeinkommen (Verlust:
$-46.51M
KGV:
-12.47
EPS:
-0.1716
Netto-Cashflow:
$-37.99M
1W Leistung:
+2.39%
1M Leistung:
-15.08%
6M Leistung:
-82.73%
1J Leistung:
-86.01%
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Vergleichen Sie CATX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CATX
Perspective Therapeutics Inc
|
2.14 | 154.77M | 6.96M | -46.51M | -37.99M | -0.1716 |
![]()
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-10-01 | Eingeleitet | Wedbush | Outperform |
2024-09-25 | Eingeleitet | Truist | Buy |
2024-07-25 | Eingeleitet | BofA Securities | Buy |
2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | CATX Stock News - GuruFocus
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - The Manila Times
Perspective Therapeutics, Inc. to Announce Q1 2025 Financial Results and Business Update on May 12, 2025 - Nasdaq
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial - Bluefield Daily Telegraph
Arrowstreet Capital Limited Partnership Has $117,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
KLP Kapitalforvaltning AS Invests $79,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - MarketBeat
Perspective Therapeutics (PSTH) Advances Trial for Melanoma Trea - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with [212 - GuruFocus
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy - MarketScreener
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - MarketScreener
Breakthrough Melanoma Treatment Shows Promise for Brain Metastasis Patients in Latest Trial - Stock Titan
Is Now The Time To Invest In Perspective Therapeutics? (NYSE:CATX) - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) Given New $10.00 Price Target at Truist Financial - Defense World
Truist cuts Perspective Therapeutics target to $10, maintains Buy By Investing.com - Investing.com South Africa
Truist cuts Perspective Therapeutics target to $10, maintains Buy - Investing.com
Paraganglioma Treatment Market Size in 7MM is expected to grow - openPR.com
Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating - marketscreener.com
CATX stock touches 52-week low at $1.87 amid market challenges - Investing.com Australia
CATX stock touches 52-week low at $1.87 amid market challenges By Investing.com - Investing.com South Africa
What is HC Wainwright’s Estimate for CATX Q2 Earnings? - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com
Pheochromocytomas and Paragangliomas Treatment Market Size - openPR.com
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance
Perspective Therapeutics director Robert Williamson buys $132,151 in stock - Investing.com Australia
Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India
Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock - Investing.com Australia
Perspective Therapeutics director Lori Woods acquires $49,999 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com South Africa
Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com India
Perspective Therapeutics (NYSE:CATX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.
Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World
Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times
Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan
Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World
CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World
HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World
Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com
Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kapitalisierung:
|
Volumen (24h):